MRKR
Marker Therapeutics, Inc.1.2700
-0.1200-8.63%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
21.17MP/E (TTM)
-Basic EPS (TTM)
-1.17Dividend Yield
0%Recent Filings
8-K
Strong MT-601 lymphoma data
Marker Therapeutics reported 2025 results, spotlighting MT-601's Phase 1 APOLLO data: 66% objective response rate in relapsed non-Hodgkin lymphoma, with 50% complete responses and no dose-limiting toxicities. Cash stands at $17 million, funding operations through Q4 2026; net loss widened to $12.2 million from $10.7 million. APOLLO updates and pancreatic program launch loom in Q2 2026. Manufacturing ramps up.
10-K
FY2025 results
Marker Therapeutics posted FY2025 grant revenue of $3.5M, down 46% y/y from $6.6M, fueling R&D spend of $11.8M (down 12% y/y) on MT-601 lymphoma and pancreatic trials plus MT-401-OTS AML/MDS work—Q4 saw first OTS patient dosing with clean safety and APOLLO updates showing 66% ORR in NHL, 78% in HL. Manufacturing costs fell sharply to $0.8M from $5.8M after Cell Ready termination, shifting to BCM ($3.2M) and new Cellipont SOW. Cash burn hit $12M on $16.8M working capital, runway to Q4 2026 sans new grants. Liquidity tightens sans fresh ATM cash. Clinical holds threaten trial momentum.
8-K
2026 AGM set May 1
Marker Therapeutics scheduled its 2026 Annual Meeting for May 1, 2026, advancing it more than 30 days from the 2025 meeting's anniversary. This triggers a new Rule 14a-8 deadline: stockholder proposals due by March 9, 2026, at Houston headquarters. Board acts in company's best interest. Deadlines shifted sharply.
8-K
Strong MT-601 data, lower loss
Marker Therapeutics reported Q3 2025 results, highlighting MT-601's 66% objective response rate and 50% complete responses in relapsed NHL patients from the APOLLO study, with durable responses up to 24 months and no DLTs or ICANS. R&D expenses fell to $2.3M from $3.5M year-over-year, driving a narrower $2.0M net loss; cash stands at $17.6M, funding operations through Q3 2026. First OTS patient treated in RAPID study.
10-Q
Q3 FY2025 results
Marker Therapeutics narrowed its Q3 operating loss to $2.1M from $2.4M y/y, while grant revenue dipped 36% to $1.2M amid shifting CPRIT/NIH funding to MT-601 and MT-401-OTS programs; R&D expenses fell 32% to $2.3M on lower clinical trials, yet YTD op loss widened to $11.0M from $7.3M (derived) with higher headcount and $0.5M vendor termination hit. Cash holds steady at $17.6M plus $1.4M restricted, bolstered by $9.9M ATM raises, funding ops to Q3 2026. EPS improved to $(0.12) from $(0.26), reconciling to 16.8M diluted shares. Cash burn continues.
IPO
Employees
Sector
Industry
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
FATE
Fate Therapeutics, Inc.
1.09-0.03
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRSN
Mersana Therapeutics, Inc.
29.05+0.46
TCRX
TScan Therapeutics, Inc.
0.95-0.01
TNGX
Tango Therapeutics, Inc.
8.96-0.16